𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Simultaneous suppression of multidrug resistance and antiapoptotic cellular defense induces apoptosis in chemoresistant human acute myeloid leukemia cells

✍ Scribed by Xiaofang Wang; Chun Wang; You-wen Qin; Shi-ke Yan; Yan-rong Gao


Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
349 KB
Volume
31
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.

✦ Synopsis


The emergence of acquired drug resistance is a major hurdle in the successful treatment of leukemia. Researches indicated that the main mechanisms of most cancers included so-called "pump" and "nonpump" resistance. We studied the mechanisms involved in the drug resistance of HL-60/ADR and found that its drug resistance was associated with the simultaneous overexpression of XIAP and MRP. We compared the reversal effects of XIAP and MRP ASO used in combination and separately. Reverse transcription-PCR and Western blot were applied to examine the changes of mRNA and protein levels, respectively. The results showed that XIAP and MRP ASO used separately could downregulate the expression of XIAP and MRP in HL-60/ADR cells, respectively. XIAP and MRP ASO used in combination did not enhance the inhibition expression of XIAP and MRP of HL-60/ADR cells. The apoptosis of co-transfection group was significantly higher than XIAP ASO (P < 0.05). The cytotoxicity was determined by MTT cell viability/proliferation assay. When used in combination the sensitivity of HL-60/ADR cells to DNR was increased significantly compared with XIAP or MRP ASO used separately (P < 0.05). The results indicated that both XIAP and MRP were involved in the drug resistance mechanisms of HL-60/ADR cells. The sensitivity to DNR could be enhanced significantly when XIAP and MRP ASO used in combination.


📜 SIMILAR VOLUMES


Resistance to 1,25D-induced differentiat
✍ Edward Garay; Robert Donnelly; Xuening Wang; George P. Studzinski 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 438 KB

## Abstract The anti‐neoplastic effects of 1,25‐dihydroxyvitamin D~3~ (1,25D) are well documented in numerous tumor cell systems and animal models of cancer. However, despite this pre‐clinical success, the clinical use of 1,25D is currently impeded by the dose‐limiting hypercalcemia, and the risk o